NCT06425120View on ClinicalTrials.gov

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Coronary Heart Disease
Interventions
DRUG

Xuesaitong Soft Capsule

Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.

DRUG

Placebo

Each participant in the placebo group will take matching placebo.

Trial Locations (2)

100087

RECRUITING

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

NOT_YET_RECRUITING

Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV